Synthesis and biological evaluation of some novel quinoxaline derivatives as anticonvulsant agents

Abdelghany Aly Elhelby; Rezk Rezk Ayyad; Mohamed Fathalla Zayed

doi:10.1055/s-0031-1296214

Arzneimittelforschung, Inhaltsverzeichnis

Arzneimittelforschung 2011; 61(7): 379-381
DOI: 10.1055/s-0031-1296214

CNS-active Drugs · Hypnotics · Psychotropics · Sedatives

Editio Cantor Verlag Aulendorf (Germany)

Synthesis and biological evaluation of some novel quinoxaline derivatives as anticonvulsant agents

Abdelghany Aly Elhelby

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt

,

Rezk Rezk Ayyad

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt

,

Mohamed Fathalla Zayed

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt

²Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Boys), Taibah University, Al-Madinah Al-munawarah, Kingdom of Saudi Arabia

› Institutsangaben

Abstract

In view of their expected anticonvulsant activity, some new derivatives of quinon-xaline (V1–7) were designed and synthesized by condensation of different aromatic aldehydes with 2-(2-oxo-3-phenyl-quinoxalin-1 (2H) -yl) acetohydrazide (IV). All synthesized compounds were isolated and confirmed by IR, 1H-NMR, MS, elemental analysis and then tested as anti-convulsant agents. Compound V3 and V1 showed the highest anticonvulsant effect with anticonvulsant potency relative to phenobarbital sodium of 0.8 and 0.75 whereas compound V5 exhibited the lowest relative potency of 0.09. The other compounds showed variable activity between these values as follows: V2 = 0.19, V4 = 0.41, V6 = 0.1 and V7 = 0.15. All compounds showed less activity than the reference compound phenobarbital. But the compounds provided a basis for further optimization.

Key words

Anticonvulsant drugs - Arylidene - Quinoxaline derivatives - Synthesis

Volltext

Referenzen

References
1 Bhosale RS, Sarda SR, Ardhapure SS, Jadhav WN, Bhusare SR, Pawar RP. An efficient protocol for the synthesis of quinoxaline derivatives at room temperature using molecular iodine as the catalyst. Tetrahedron Lett. 2005; 46: 7183-6
2 Abu-Hashem AA, Gouda MA, Badria FA. Synthesis of some new pyrimido[2’,1’:2,3]thiazolo[4,5-fc]quinoxaline derivatives as anti-inflammatory and analgesic agents. Eur J Med Chem. 210; 45: 1976-81
3 Chapman AG, Smith SE, Meldrum BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466 in mice. Epilepsy Res. 1991; 2: 92-6
4 Wagle S, Adhikari AV, Kumari NS. Synthesis of some new 4-styryltetrazolo[1,5-a]quinoxaline and l-substituted-4-styryl [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potent anticonvulsants. Eur J Med Chem. 2009; 44: 1135-43
5 Kessler M, Baudry M, Lynch G. Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites. Brain Res. 1989; 2: 377-82
6 Soaje-Echaque E, Lim RKS. Anticonvulsant activity of some carbinylureas. Pharmacol Exp Ther. 1962; 138: 224-8
7 Arnowski TZ, Kleinrok Z, Turski WA, Czuczwar SJ. 2,3-dihy-droxy-6-nitro-7-sulfamoylbenzo(F) quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993; 32: 895-900
8 Varano F, Catarzi D, Colotta V, Cecchi L, Filacchioni G, Galli A et al. Synthesis of a set of ethyl I-carbamoyl-3-oxo-quinoxaline-2-carboxylates and of their constrained analogue imidazo[1,5-a]quinoxaline-1,3,4-triones as glycine/ NMDA receptor antagonists. Eur J Med Chem. 2001; 36: 203-9